- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Qbrelis, Prinivil, Zestril
Synonyms :
Class :
Angiotensin Converting Enzyme (ACE) Inhibitors
Dosage Forms & Strengths
Tablet
2.5mg
5mg
10mg
20mg
30mg
40mg
Oral solution
1mg/mL
Initial dose: 10 mg orally daily
Maintenance dose: 20-40 mg orally daily
Maximum dose: 80 mg orally daily
systolic congestive heart failure
2.5-5 mg orally daily; may be increase to 40 mg orally daily
5 mg orally (onset of symptoms of acute MI);
Subsequent dose of 5 mg orally after 24 hours, and 10 mg orally after 48 hours.
and increase 10 mg orally daily 6 weeks.
10 - 20
mg
orally
daily; may be increase to 20-40 mg orally daily
Dosage Forms & Strengths
Tablet
2.5mg
5mg
10mg
20mg
30mg
40mg
Oral solution
1mg/mL
Age: >6 years
0.07 mg/kg orally daily; increase up to 5 mg once a day; Dosage adjusted for 1–2-week intervals.
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
angiotensin II Receptor Blockers may enhance the adverse/toxic effect of angiotensin-Converting Enzyme Inhibitors
may increase the toxic effect of angiotensin receptor II blockers
may increase the toxic effect of angiotensin receptor II blockers
may diminish the serum concentration when combined with angiotensin-converting enzyme inhibitors
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increasingly adverse effect when combined with NSAIDs
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may increase the risk of neutropenia
choline magnesium trisalicylate
salicylates may enhance the nephrotoxic effect of ACE Inhibitors
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
Icatibant may diminish the effect of ACE Inhibitors
choline magnesium trisalicylate
may enhance the nephrotoxic effect of ACE inhibitors
may have an increasingly adverse effect when combined with alteplase
polyethylene glycol and electrolytes
They may increase the nephrotoxic effect when combined with polyethylene Glycol-electrolyte Solution
Dipeptidyl Peptidase-IV Inhibitors: they may increase the toxic effect of angiotensin-converting enzyme inhibitors
Dipeptidyl Peptidase-IV Inhibitors: they may increase the toxic effect of angiotensin-converting enzyme inhibitors
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
Nonsteroidal Anti-Inflammatory Agents: they may decrease the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors
may have an increasingly adverse effect when combined with iron dextran complex
spironolactone and hydrochlorothiazide
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
probenecid may enhance the effects of lisinopril through an unidentified interaction mechanism
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
angiotensin II receptor blockers increase the toxicity of ACE inhibitors
Adverse drug reactions:
Frequency Defined
>10%
Heart failure
Hypotension
Hypertension
Dizziness
Cough
1-10%
Heart failure
Syncope
Creatinine increased
Hyperkalemia
Hypotension
Diarrhea
Rash
Infection
Chest pain
Abdominal pain
≥1%
Angina pectoris
Asthenia
Cough
Nausea
Dyspnea
Pruritus
Hypertension
Headache
Increased BUN and serum creatinine
Dizziness
Hyperkalemia
Pregnancy warnings:
AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned
Lactation:
Excreted into human milk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: lisinopril
Why do we use lisinopril?
lisinopril is an Angiotensin Converting Enzyme (ACE) Inhibitors. It is used to treat Hypertension, MI, Systolic (congestive) heart failure, and Diabetic Nephropathy.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
